CN110590811B - Preparation method of cefuroxime axetil-3-ene isomer - Google Patents
Preparation method of cefuroxime axetil-3-ene isomer Download PDFInfo
- Publication number
- CN110590811B CN110590811B CN201910921254.XA CN201910921254A CN110590811B CN 110590811 B CN110590811 B CN 110590811B CN 201910921254 A CN201910921254 A CN 201910921254A CN 110590811 B CN110590811 B CN 110590811B
- Authority
- CN
- China
- Prior art keywords
- cefuroxime axetil
- alkene
- isomer
- cefuroxime
- isomeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001668 cefuroxime Drugs 0.000 title claims abstract description 24
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 36
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims abstract description 58
- 229960002620 cefuroxime axetil Drugs 0.000 claims abstract description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000010 aprotic solvent Substances 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000000825 ultraviolet detection Methods 0.000 claims abstract description 5
- 238000004262 preparative liquid chromatography Methods 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003586 protic polar solvent Substances 0.000 claims description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- -1 3-ethylamine Chemical compound 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 238000005815 base catalysis Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000003908 quality control method Methods 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 description 24
- 238000001514 detection method Methods 0.000 description 17
- 238000000746 purification Methods 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000004811 liquid chromatography Methods 0.000 description 8
- 238000005191 phase separation Methods 0.000 description 8
- 238000002390 rotary evaporation Methods 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a preparation method of cefuroxime axetil-3-alkene isomer, belonging to the medicine quality research, quality control and safety research of pharmaceutical enterprises and disclosing the step (1): in an aprotic solvent and a protic solution, the cefuroxime axetil generates 3-alkene isomeric cefuroxime axetil and a mixture of cefuroxime axetil under the action of base catalysis; step (2): and (2) purifying the mixture of cefuroxime axetil and 3-alkene isomeric cefuroxime axetil obtained in the step (1) by a reversed phase C18 column preparative liquid chromatography under the conditions of water/methanol (40/60), flow rate of 40ml/min and ultraviolet detection wavelength of 23nm, extracting, drying and concentrating to obtain the cefuroxime axetil-3-alkene isomer. The invention has simple reaction operation, mild condition and high product purity, and the obtained cefuroxime axetil-3-ene isomer can be used as a standard substance to be applied to the quality control of cefuroxime axetil bulk drugs and preparations.
Description
Technical Field
The invention belongs to the technical field of medicines, and relates to a preparation method of cefuroxime axetil-3-ene isomer.
Technical Field
Cefuroxime is a cephalosporin antibiotic developed by Kuran Smith company, is firstly marketed in the United states in 1988 and expires in 1996, and is taken as the second generation oral cephalosporin, so that the medicine has strong lipid solubility and good oral absorption; cefuroxime axetil is an esterified cefuroxime, which is hydrolyzed in vivo to release cefuroxime and exert its antibacterial activity; the latter has wide antibacterial spectrum, strong antibacterial effect and stability to lactamase. Cefuroxime axetil has very low antibacterial activity, and after being absorbed orally for 3-4 min, it is hydrolyzed fast by non-specific esterase in intestinal mucosa and portal circulation to release cefuroxime and exert its antibacterial action, so that the antibacterial spectrum and antibacterial activity of cefuroxime axetil are the same as those of cefuroxime. The traditional Chinese medicine composition is mainly used for treating mild and moderate respiratory tract infection, urogenital system infection, skin and soft tissue infection, gonorrhea and the like caused by sensitive bacteria clinically.
The 3-ene isomeric cefuroxime axetil is produced due to the ectopic carbon-carbon double bond in the six-membered ring structure of beta-lactam, and the 3-ene isomeric cefuroxime axetil (or referred to as cefuroxime axetil-3-ene isomer) is far from efficacious in comparison with cefuroxime axetil. Therefore, the control of 3-alkene isomeric cefuroxime axetil is necessary in the production process of bulk drugs and preparations. In the quality study of cefuroxime axetil, the 3-alkene isomer thereof was used as a drug impurity for control study.
Disclosure of Invention
The invention aims to provide a method for preparing 3-alkene isomeric cefuroxime axetil (or referred to as cefuroxime axetil-3-alkene isomer) with simple operation and mild conditions.
For cephalosporin antibiotic preparations, the carbon-carbon double bond on the beta-lactam ring can mostly generate 0.1 to 0.5 percent of 3-alkene isomer in the long-term sample retention process. 0.5% of the 3-ene isomer is a concept of high impurity level in quality control, but if it is used for preparing a dry product in which the 3-ene isomer is pure, 0.5% of the 3-ene isomer is a concept of low content level, and if it is purified and enriched from the 0.5% level, it takes a lot of manpower and material resources, which is apparently not a good solution.
According to the invention, researches show that the cefuroxime axetil solid powder has low content of generated 3-alkene isomer, only about 2-5% under high-temperature damage, and the time consumption is long, and needs 5-10 days. The cefuroxime axetil is dissolved and dispersed in an organic solvent, and can generate 40-65% of 3-alkene isomer in a short time by adding base catalysis, and other impurities are few, so that the subsequent separation and purification operation is convenient.
According to the invention, researches show that the concentration of cefuroxime axetil in the organic solvent also has an influence on the effect of generating the 3-alkene isomer through base catalytic destruction, and when the concentration is more than 0.3g/ml, the content of the 3-alkene isomer is sharply reduced and is only about 15%. At a concentration of 0.1g/ml, the content of 3-ene isomers produced by base catalysis is the highest, about 65%.
According to the invention, researches show that aprotic solvents such as ethyl acetate, tetrahydrofuran, dioxane, acetonitrile, dichloromethane and acetone and protic solvents such as methanol, ethanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol and glycerol can be used for dissolving cefuroxime axetil to generate 3-alkene isomers with high purity level. In a dichloromethane system, the content of 3-alkene isomeric cefuroxime axetil generated by base catalytic destruction in the organic solvent is at most about 65 percent. The most impurities of 3-alkene isomeric cefuroxime axetil are generated by the base catalytic destruction of a methanol system, and the separation and purification efficiency is influenced.
According to the invention, the base catalysis time needs to be proper through research. The time is too short, the cefuroxime axetil raw material is not damaged enough, and the generated 3-alkene isomer is less. For a long time, cefuroxime axetil and 3-alkene isomer are destroyed to generate many other impurities, which makes separation and purification difficult. When a certain amount of 3-ene isomer is produced, the increase of the base catalysis time is not continued, but the produced 3-ene isomer is destroyed because of the increase of the base catalysis time.
According to the invention, researches show that the catalytic effect of the organic base is better than that of inorganic base, the effect of piperidine and morpholine in the organic base is the best, and the purity of the 3-alkene isomer of the furoyl ester can reach 60-65%.
The invention adopts reversed phase C18 column to separate and purify cefuroxime axetil and the 3-alkene isomer mixture thereof, the chromatographic condition is that water/methanol is 40/60, the flow rate is 40ml/min, and the wavelength of the ultraviolet detector is 230 nm. The organic phase ratio is more than 60 percent, the peak of the furoyl-3-ene isomer and the main peak of the furoyl ester are overlapped, the organic phase ratio is less than 50 percent, the separation degree of the furoyl-3-ene isomer peak and the main peak of the furoyl ester is good, but the peaks are flat, the number of tower plates is low, the collected fraction is large, and the concentration of the 3-ene isomer is low. The polarity difference between the main peak of the furoyl ester and the furoyl ester-3-alkene isomer peak is not large, and the peak positions are very close in liquid chromatogram, so acetonitrile can not be used as an organic phase, and the main peak and the isomer peak can not be effectively separated because the elution capacity of the acetonitrile is too strong. And other impurities with insufficient ultraviolet absorption can be conveniently observed by adopting the wavelength of 230 nm. If the chromatographic separation condition adopts a buffer salt system such as acetate, phosphate and the like, the 3-alkene isomeric cefuroxime axetil can react with the organic phase methanol to generate cefuroxime methyl ester due to the ion catalytic effect, so that the purity of the finished product is greatly reduced, and secondary purification preparation is required.
The preparation of the 3-alkene isomeric cefuroxime axetil comprises the following two steps:
step (1): weighing 10g of cefuroxime axetil, adding 100ml of dichloromethane, stirring for dissolving, then adding 1ml of 3-ethylamine, stirring for reacting for 6 hours at room temperature to obtain 55% purity 3-alkene isomeric cefuroxime axetil, and mixing;
step (2): separating and purifying the 3-alkene isomer mixture obtained in the step (1) by a reversed phase C18 column, wherein the chromatographic conditions of purification are that water/methanol is 40/60, the flow rate is 40ml/min, and the ultraviolet detection wavelength is 230 nm. Collecting the target fraction, enriching and collecting, extracting with ethyl acetate, drying with anhydrous sodium sulfate, filtering, and rotary evaporating to obtain 3-alkene isomeric cefuroxime axetil with the purity of 98%.
The method for preparing 3-alkene isomeric cefuroxime axetil in the step (1) is characterized in that the aprotic solvent used for preparing the cefuroxime axetil solution in the step (1) is ethyl acetate, tetrahydrofuran, dioxane, acetonitrile, dichloromethane or acetone, and the protic solvent is one of methanol, ethanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol and glycerol; the dosage of the alkali is 0.1 to 1 time, the reaction time is 4 to 12 hours, and the purity of the 3-alkene isomeric cefuroxime axetil is 40 to 65 percent
The purification preparation conditions in the step (2) are reversed phase C18 column, mobile phase is water/methanol 40/60, and ultraviolet detection wavelength is 230 nm. And in the enrichment fraction treatment, the extraction solvent is ethyl acetate, dichloromethane, chloroform and carbon tetrachloride.
The invention has the advantages that: the preparation method of 3-alkene isomeric cefuroxime axetil, which has the advantages of simple operation, mild conditions and low cost, is provided, the obtained 3-alkene isomeric cefuroxime axetil has high purity, and can be used as an impurity reference substance to be applied to the quality control research of cefuroxime axetil raw material medicines and preparations. Compared with the purchased reference substance, the method has great cost advantage. Compared with other literature reports, the ultraviolet irradiation damage method of the invention can produce the cefuroxime axetil with the highest purity of 3-alkene isomer, thereby greatly saving the cost for producing the pure product of the cefuroxime axetil with the 3-alkene isomer.
Detailed Description
EXAMPLE 1 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, 100ml of an aprotic solvent in methylene chloride was added and dissolved with stirring, and 1ml of 3-ethylamine was added and stirred at room temperature for 4 hours. The isomeric 3-ene cefuroxime axetil was detected by HPLC to be about 50%. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. After gathering and enriching the prepared liquid phase of each target fraction, extracting with dichloromethane, drying with anhydrous sodium sulfate, and then carrying out reduced pressure rotary evaporation at 40 ℃ to obtain 4.2g of gray yellow foamy solid, wherein the purity is 96.5% by liquid chromatography detection.
EXAMPLE 2 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, dissolved in 100ml of tetrahydrofuran which is an aprotic solvent under stirring, and then 10ml of 3-ethylamine was added thereto under stirring at room temperature for 6 hours. By HPLC detection, 3-ene isomeric cefuroxime axetil was about 49%. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. After gathering and enriching the prepared liquid phase per-needle target fraction, extracting with chloroform, drying with anhydrous sodium sulfate, and then performing reduced pressure rotary evaporation at 40 ℃ to obtain 4g of gray yellow foamy solid, wherein the purity is 96.9% by liquid chromatography detection.
EXAMPLE 3 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, 100ml of dioxane as an aprotic solvent was added and dissolved by stirring, and 5ml of piperidine was added and stirred at room temperature for 4 hours. The isomeric 3-ene cefuroxime axetil was found to be about 59% by HPLC. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. After gathering and enriching the prepared liquid phase per needle target fraction, extracting with carbon tetrachloride, drying with anhydrous sodium sulfate, and then performing rotary evaporation at 40 ℃ under reduced pressure to obtain 5g of gray yellow foamy solid, wherein the purity is 98.5% by liquid chromatography detection.
EXAMPLE 4 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, dissolved in 100ml of methylene chloride as an aprotic solvent with stirring, and then 5ml of morpholine was added thereto with stirring at room temperature for 7 hours. The isomeric 3-ene cefuroxime axetil was found to be about 65% by HPLC. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. Gathering and enriching the prepared liquid phase per-needle target fraction, extracting with ethyl acetate, drying with anhydrous sodium sulfate, and performing reduced pressure rotary evaporation at 40 ℃ to obtain 5.9g of gray yellow foamy solid, wherein the purity is 97.9% through liquid chromatography detection.
EXAMPLE 5 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, dissolved in 100ml of acetone as an aprotic solvent under stirring, and then 10ml of pyridine was added thereto, and stirred at room temperature for 5 hours. The isomeric 3-ene cefuroxime axetil was found to be about 43% by HPLC. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. After gathering and enriching the prepared liquid phase of each target fraction, extracting with dichloromethane, drying with anhydrous sodium sulfate, and then carrying out reduced pressure rotary evaporation at 40 ℃ to obtain 3.5g of gray yellow foamy solid, wherein the purity is 95.5% by liquid chromatography detection.
EXAMPLE 6 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, 100ml of methanol as a protic solvent was added and dissolved by stirring, and 10g of potassium carbonate was added and stirred at room temperature for 12 hours. The isomeric 3-ene cefuroxime axetil was found to be about 40% by HPLC. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. After gathering and enriching the prepared liquid phase of each target fraction, extracting with dichloromethane, drying with anhydrous sodium sulfate, and then carrying out reduced pressure rotary evaporation at 40 ℃ to obtain 3.1g of gray yellow foamy solid, wherein the purity is 94.9% by liquid chromatography detection.
EXAMPLE 7 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, added to 100ml of glycerol as a protic solvent, and stirred to dissolve, then 10g of cesium carbonate was added thereto, and stirred at room temperature for 12 hours. The 3-ene isomeric cefuroxime axetil was detected by HPLC to be about 40%. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: 40/60, flow rate 40ml/min, ultraviolet detection wavelength 230 nm. After gathering and enriching the prepared liquid phase of each target fraction, extracting with dichloromethane, drying with anhydrous sodium sulfate, and then carrying out reduced pressure rotary evaporation at 40 ℃ to obtain 3.0g of gray yellow foamy solid, wherein the purity is 95.5% by liquid chromatography detection.
EXAMPLE 8 preparation of cefuroxime axetil-3-ene isomer
10g of cefuroxime axetil was weighed, 100ml of acetonitrile as an aprotic solvent was added and dissolved by stirring, and 2ml of diethylamine was added and stirred at room temperature for 7 hours. By HPLC detection, 3-ene isomeric cefuroxime axetil was about 49%. Then the product is separated and purified by a preparation liquid phase C18 column. The preparation liquid phase separation and purification conditions are as follows: water/methanol 40/60, flow rate 40ml/min, uv detection wavelength 230 nm. After gathering and enriching the prepared liquid phase of each target fraction, extracting with dichloromethane, drying with anhydrous sodium sulfate, and then carrying out reduced pressure rotary evaporation at 40 ℃ to obtain 4g of gray yellow foamy solid, wherein the purity is 97.5% by liquid chromatography detection.
Claims (3)
1. A method for preparing cefuroxime axetil-3-ene isomers, which comprises:
step (1): dissolving cefuroxime axetil in one of an aprotic solvent or a protic solvent to prepare a cefuroxime axetil solution with the concentration of 0.1g/ml, then adding 0.1-1 time of alkali, and stirring and reacting at room temperature for 4-12 hours to obtain a cefuroxime axetil mixture containing 40-65% of 3-alkene isomeric cefuroxime axetil;
step (2): purifying the mixture of cefuroxime axetil and the 3-alkene isomer thereof obtained in the step (1) by reversed phase C18 preparative liquid chromatography under the conditions of water/methanol =40/60, flow rate of 40ml/min and ultraviolet detection wavelength of 230nm, collecting corresponding fractions, extracting, drying and rotary evaporating to obtain a dry cefuroxime axetil-3-alkene isomer;
the aprotic solvent is ethyl acetate, tetrahydrofuran, dioxane, acetonitrile, dichloromethane or acetone;
protic solvents such as methanol, ethanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol, glycerol;
the alkali is sodium carbonate, potassium carbonate, cesium carbonate, 3-ethylamine, diethylamine, pyridine, piperidine or morpholine.
2. The process of claim 1, wherein the reaction time in step (1) is 4-12 hours.
3. The method according to claim 1, wherein the solvent used in the extraction in step (2) is ethyl acetate, dichloromethane, chloroform or carbon tetrachloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910921254.XA CN110590811B (en) | 2019-09-27 | 2019-09-27 | Preparation method of cefuroxime axetil-3-ene isomer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910921254.XA CN110590811B (en) | 2019-09-27 | 2019-09-27 | Preparation method of cefuroxime axetil-3-ene isomer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110590811A CN110590811A (en) | 2019-12-20 |
| CN110590811B true CN110590811B (en) | 2022-05-03 |
Family
ID=68863885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910921254.XA Active CN110590811B (en) | 2019-09-27 | 2019-09-27 | Preparation method of cefuroxime axetil-3-ene isomer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110590811B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1265061B1 (en) * | 1993-08-06 | 1996-10-28 | Dompe Spa | VALIDES OF 7ALPHA-AMINO-1, 1-DIOXO-CEFEM |
| IN181290B (en) * | 1997-06-23 | 1998-05-02 | C O J K Ind Ltd | |
| US7064198B2 (en) * | 2001-07-25 | 2006-06-20 | Lupin Limited | Method for preparation of cefuroxime axetil |
| RU2015120084A (en) * | 2012-10-29 | 2016-12-27 | Сионоги Энд Ко., Лтд. | METHODS FOR PRODUCING INTERMEDIATE COMPOUNDS FOR 2-ALKYL CEPHEMIC COMPOUNDS |
| CN103450224A (en) * | 2013-08-29 | 2013-12-18 | 东北制药集团股份有限公司 | Preparation method of delta3 isomer of cefoselis |
-
2019
- 2019-09-27 CN CN201910921254.XA patent/CN110590811B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110590811A (en) | 2019-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101696210B (en) | High-purity antibiotic medicinal compound | |
| US10189769B2 (en) | Method for preparation of pharmaceutically acceptable chlorogenic acid | |
| CN102718843B (en) | Preparation method of single teicoplanin components | |
| CN102465164B (en) | Preparation method of pristinamycin | |
| CN103936837A (en) | Method used for high-efficient purification of pneumocandins B0 | |
| CN102234283A (en) | 4'-demethyl epipodophyllotoxin derivatives, and synthesis method and application thereof | |
| CN110590811B (en) | Preparation method of cefuroxime axetil-3-ene isomer | |
| CN106432276A (en) | Cefazolin sodium compound prepared according to novel intelligent crystallization technology and preparation of cefazolin sodium compound | |
| CN106226426A (en) | A kind of high performance liquid chromatography splits the method for canagliflozin five-membered ring impurity enantiomer | |
| CN113582951B (en) | 10- (S) -17-hydrogen-7-dehydroandrographolide and industrial chromatographic preparation method and application thereof | |
| CN110627814A (en) | Preparation method of cefuroxime sodium methoxyimino isomer | |
| CN110746302B (en) | Method for separating and preparing phenolic acid compounds in echinacea purpurea | |
| CN105175426B (en) | A kind of method of the extraction purification Bergenin from treebine stem | |
| CN107141335A (en) | A kind of cyclic peptide compounds and its preparation method and application | |
| CN108822014B (en) | Synthetic method of avibactam intermediate | |
| CN108169399B (en) | Method for separating impurities in ethyl demethylaminothiazolyloximate crude product | |
| CN110627813A (en) | Preparation method of cefuroxime axetil methoxyimino isomer | |
| CN117142936A (en) | Preparation method of euphorbia lunata extract A | |
| CN113670680B (en) | Preparation method of acarbose impurity reference substance | |
| CN109081837A (en) | The method for separating and preparing of mezlocillin sodium impurity A | |
| PT2837630T (en) | Method for synthesizing sapropterin dihydrochloride | |
| SU1207396A3 (en) | Method of isolating vincristine | |
| CN106117244A (en) | The process for purification of Cefditoren pivoxil Cephalosporins | |
| CN116254314A (en) | Synthesis method of cefotaxime impurity E | |
| CN105566268B (en) | A kind of method for preparing purified of red yeast rice Lovastatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |